David A. Siegel Harmony Biosciences Holdings, Inc. Transaction History
Two Sigma Advisers, LP
- $41.3 Billion
- Q3 2024
A detailed history of David A. Siegel (Two Sigma Advisers, LP) transactions in Harmony Biosciences Holdings, Inc. stock. As of the latest transaction made, Two Sigma Advisers, LP holds 81,200 shares of HRMY stock, worth $2.77 Million. This represents 0.01% of its overall portfolio holdings.
Number of Shares
81,200
Previous 92,700
12.41%
Holding current value
$2.77 Million
Previous $2.8 Million
15.99%
% of portfolio
0.01%
Previous 0.01%
Shares
11 transactions
Others Institutions Holding HRMY
# of Institutions
242Shares Held
45.2MCall Options Held
108KPut Options Held
49.2K-
Valor Management LLC Chicago, IL11.2MShares$382 Million100.0% of portfolio
-
Black Rock Inc. New York, NY5.84MShares$199 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA3.47MShares$118 Million0.0% of portfolio
-
Vivo Capital, LLC Palo Alto, CA2.61MShares$88.8 Million15.24% of portfolio
-
Pacer Advisors, Inc. Malvern, PA1.93MShares$65.7 Million0.18% of portfolio
About Harmony Biosciences Holdings, Inc.
- Ticker HRMY
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 59,161,400
- Market Cap $2.02B
- Description
- Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, develops and commercializes therapies for patients with rare neurological disorders in the United States. Its product, WAKIX is a medication for the treatment of excessive daytime sleepiness in adult patients with narcolepsy. The company was formerly known as Harmony ...